Detalhe da pesquisa
1.
Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
N Engl J Med;
373(13): 1195-206, 2015 Sep 24.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26214039
2.
Tetravalent Dengue Vaccine Reduces Symptomatic and Asymptomatic Dengue Virus Infections in Healthy Children and Adolescents Aged 2-16 Years in Asia and Latin America.
J Infect Dis;
214(7): 994-1000, 2016 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27418050
3.
Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
JAMA;
310(11): 1145-55, 2013 Sep 18.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23995608
4.
Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
Am Heart J;
164(6): 817-24.e13, 2012 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-23194481
5.
Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014).
Trans R Soc Trop Med Hyg;
112(4): 158-168, 2018 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29800279